We use technology to improve diagnostic and treatment accuracy for patients. We develop state of the art solutions to improve clinical outcome, and hence improve quality of life.
Biobot Surgical Pte Ltd aims to be a global technology leader in minimally-invasive robotic healthcare solutions.
Biobot Surgical Pte Ltd was incorporated in 2007 in Singapore, and became a member of Zicom Group since 2011.
To ensure success, a team of talents has been put together in the areas of robotic design and technology, medical image processing, software development and clinical application. In addition, Zicom leveraged its in-house intellectual property (IP) translation services and manufacturing infrastructure from iPtec to support the project.
To date, the iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), U.S.A (US FDA), Australia (TGA) and Singapore (HSA) and is being used in some of the most prestigious hospitals around the world.
Striving to become the gold standard in diagnosis and prognosis of prostate cancer, the Mona Lisa’s development has been a process of evolution and is the latest in our state of the art new generation designs.
“It is certainly a game-changer. This machine will make prostate biopsy much more accessible, feasible and more accurate for the patients”
-Dr Devang Desai, Urologist
In the upcoming UroFair 2018, Biobot Surgical is proud to be a sponsor of the Masterclass: MRI-Ultrasound Targeted Prostate Biopsy – 13 July, 1030am – 1230pm.
UroFair 2018 takes place on 12-14 July 2018 at Grand Hyatt, Singapore.
This conference is organised by the Singapore Urological Association.
Mona Lisa is one of the success stories in Singapore’s medtech scene
Mona Lisa helps Singapore General Hospital achieve an increase from 70% to 90% accuracy in biopsy tests for cancer.